FR24C1041I1 - FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD - Google Patents

FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD

Info

Publication number: FR24C1041I1
Authority: FR; France
Prior art keywords: factor; production method; polypeptide mutant; mutant; polypeptide
Prior art date: 2008-09-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR24C1041C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Uniqure Biopharma BV

Original Assignee

Uniqure Biopharma BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-15

Filing date

2024-10-30

Publication date

2024-12-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1041(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-15 Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/en

2009-05-06 Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/en

2024-10-30 Application filed by Uniqure Biopharma BV filed Critical Uniqure Biopharma BV

2024-12-06 Publication of FR24C1041I1 publication Critical patent/FR24C1041I1/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

FR24C1041C 2008-09-15 2024-10-30 FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD Active FR24C1041I1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
ITBO2008A000564A IT1394177B1 (en)	2008-09-15	2008-09-15	POLYPEPTIDE FACTOR IX MODIFIED, ITS USE AND METHOD FOR ITS PRODUCTION
ITBO2009A000275A IT1395980B1 (en)	2009-05-06	2009-05-06	POLYPEPTIDE FACTOR IX MODIFIED, ITS USE AND METHOD FOR ITS PRODUCTION
EP17175191.0A EP3252157A1 (en)	2008-09-15	2009-09-15	Factor ix polypeptide mutant, its uses and a method for its production
PCT/EP2009/061935 WO2010029178A1 (en)	2008-09-15	2009-09-15	Factor ix polypeptide mutant, its uses and a method for its production
EP09748260.8A EP2337849B1 (en)	2008-09-15	2009-09-15	Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number	Publication Date
FR24C1041I1 true FR24C1041I1 (en)	2024-12-06

Family

ID=41397565

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
FR23C1028C Active FR23C1028I1 (en)	2008-09-15	2023-07-26	FACTOR IX POLYPEPTIDE MUTANT, USES THEREOF AND PRODUCTION METHOD THEREFOR
FR24C1041C Active FR24C1041I1 (en)	2008-09-15	2024-10-30	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD
FR24C1040C Active FR24C1040I1 (en)	2008-09-15	2024-10-30	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD
FR25C1004C Active FR25C1004I1 (en)	2008-09-15	2025-01-21	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR23C1028C Active FR23C1028I1 (en)	2008-09-15	2023-07-26	FACTOR IX POLYPEPTIDE MUTANT, USES THEREOF AND PRODUCTION METHOD THEREFOR

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
FR24C1040C Active FR24C1040I1 (en)	2008-09-15	2024-10-30	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD
FR25C1004C Active FR25C1004I1 (en)	2008-09-15	2025-01-21	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD

Country Status (19)

Country	Link
US (13)	US9249405B2 (en)
EP (5)	EP3252157A1 (en)
CA (1)	CA2737094C (en)
CY (2)	CY1125885T1 (en)
DK (2)	DK2337849T3 (en)
ES (3)	ES2985035T3 (en)
FI (5)	FI3581650T3 (en)
FR (4)	FR23C1028I1 (en)
HK (1)	HK1244507A1 (en)
HR (2)	HRP20230259T1 (en)
HU (6)	HUE061345T2 (en)
LT (5)	LT3581650T (en)
NO (2)	NO2023029I1 (en)
PL (3)	PL2337849T3 (en)
PT (1)	PT3581650T (en)
SI (1)	SI3581650T1 (en)
SM (2)	SMT202300084T1 (en)
TR (1)	TR201813067T4 (en)
WO (1)	WO2010029178A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9249405B2 (en)	2008-09-15	2016-02-02	Paolo Simioni	Factor IX polypeptide mutant, its uses and a method for its production
TWI595004B (en)	2010-11-03	2017-08-11	介控生化科技公司	Modified ninth factor multi-peptide and use thereof
WO2014018120A1 (en)	2012-07-25	2014-01-30	Catalyst Biosciences, Inc.	Modified factor x polypeptides and uses thereof
PL2956477T5 (en)	2013-02-15	2024-05-27	Bioverativ Therapeutics Inc.	Optimized factor viii gene
WO2016004113A1 (en)	2014-06-30	2016-01-07	Biogen Ma Inc.	Optimized factor ix gene
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
CA2990193A1 (en)	2015-06-23	2016-12-29	The Children's Hospital Of Philadelphia	Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
PT3411478T (en)	2016-02-01	2022-09-13	Bioverativ Therapeutics Inc	OPTIMIZED FACTOR VIII GENES
EP3491008A2 (en)	2016-07-26	2019-06-05	BioMarin Pharmaceutical Inc.	Novel adeno-associated virus capsid proteins
CN106497949A (en) *	2016-10-14	2017-03-15	上海交通大学医学院附属瑞金医院	Preparation and application of high-activity blood coagulation factor IX mutant, recombinant protein and fusion protein
MX2019013836A (en)	2017-05-22	2020-01-30	Baxalta Inc	Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b.
IL271957B2 (en)	2017-07-10	2024-02-01	Uniqure Ip Bv	Means and methods for aav gene therapy in humans
US11491212B1 (en)	2017-09-27	2022-11-08	Catalyst Biosciences, Inc.	Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3790627A2 (en)	2018-05-09	2021-03-17	BioMarin Pharmaceutical Inc.	Methods of treating phenylketonuria
TW202005978A (en)	2018-05-14	2020-02-01	美商拜奧馬林製藥公司	Novel liver targeting adeno-associated viral vectors
JP2021523198A (en)	2018-05-14	2021-09-02	ビオマリンプハルマセウトイカルインコーポレイテッド	Stable expression of AAV vector in juvenile subjects
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
CN112739818A (en) *	2018-08-20	2021-04-30	Ucl商业有限责任公司	Nucleotides encoding factor IX
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
UY38389A (en) *	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
EP3867380A2 (en)	2018-10-18	2021-08-25	Intellia Therapeutics, Inc.	Compositions and methods for expressing factor ix
WO2021067389A1 (en)	2019-09-30	2021-04-08	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
WO2021154414A2 (en)	2020-01-29	2021-08-05	Catalyst Biosciences, Inc.	Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US12173307B2 (en)	2020-06-24	2024-12-24	Bioverativ Therapeutics Inc.	Methods for the purification of viral vectors
EP4362971A1 (en) *	2021-07-01	2024-05-08	CSL Behring Lengnau AG	Factor ix subcutaneous administration with enhanced safety
WO2025022005A1 (en) *	2023-07-26	2025-01-30	Le Quellec Sandra	Intranasal administration of factor ix polypeptides

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0107278B1 (en)	1982-08-04	1989-11-15	National Research Development Corporation	Molecular cloning of the gene for human anti-haemophilic factor ix
US5171569A (en)	1985-03-15	1992-12-15	National Research Development Corporation	Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en)	1987-08-28	1991-02-19	Davie Earl W	DNA preparation of Christmas factor and use of DNA sequences
US5583107A (en)	1990-09-04	1996-12-10	Cor Therapeutics, Inc.	Agents affecting thrombosis and hemostasis
US5223408A (en)	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
GB9408717D0 (en)	1994-05-03	1994-06-22	Biotech & Biolog Scien Res	DNA sequences
US6227618B1 (en)	1996-02-23	2001-05-08	Schukra Usa, Inc.	Cable attachment for a lumbar support
JP3553970B2 (en)	1996-06-11	2004-08-11	ロシュダイアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	Recombinant blood coagulation protease
US6315995B1 (en)	1996-09-27	2001-11-13	The Trustees Of Columbia University In The City Of New York	Methods for treating an ischemic disorder and improving stroke outcome
CA2280700A1 (en)	1997-02-14	1998-08-20	American Red Cross	Expression of active human factor ix in mammary tissue of transgenic animals
WO1999003496A1 (en)	1997-07-21	1999-01-28	The University Of North Carolina At Chapel Hill	Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6759050B1 (en)	1998-12-03	2004-07-06	Avigen, Inc.	Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6610906B1 (en)	1999-06-09	2003-08-26	The Regents Of The University Of Michigan	Nucleotide sequences for gene regulation and methods of use thereof
US7109170B2 (en)	1999-06-16	2006-09-19	Saint Louis University	Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en)	2000-03-22	2001-09-27	The Children's Hospital Of Philadelphia	Modified blood clotting factors and methods of use
WO2002004544A2 (en)	2000-07-06	2002-01-17	Guilford Pharmaceuticals	Polymers and polymerization processes
AU2002226028A1 (en)	2000-11-14	2002-05-27	Board Of Regents, Unversity Of Texas Systems	Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en)	2002-03-11	2004-07-08	Cooper Julian D.	Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en)	2001-05-31	2002-12-05	D. Collen Research Foundation Vzw	Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
MXPA04001982A (en)	2001-09-04	2004-06-07	Merck Patent Gmbh	Modified factor ix.
US7179617B2 (en)	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en)	2002-04-04	2004-01-15	Kay Mark A.	Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
WO2003089612A2 (en)	2002-04-17	2003-10-30	University Of Florida Research Foundation, Inc.	IMPROVED rAAV VECTORS
JP5376747B2 (en)	2002-10-02	2013-12-25	カタリストバイオサイエンシーズ，インコーポレイテッド	Methods for producing and screening proteases with altered specificity
JP4559429B2 (en)	2003-05-21	2010-10-06	ジェンザイム・コーポレーション	Method for producing a recombinant AAV virion preparation substantially free of empty capsids
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
MX2007001294A (en)	2004-08-17	2008-03-04	Zlb Behring Gmbh	Modified vitamin k dependent polypeptides.
EP1627771B1 (en)	2004-08-19	2008-10-15	Gerd Bär	Loading platform with transversaly shiftable connection tube
WO2006031226A1 (en)	2004-09-13	2006-03-23	Saint Louis University	Region of factor ixa protease domain that interacts with factor viiia and methods therefor
DK2438931T3 (en)	2004-09-22	2013-12-02	St Jude Childrens Res Hospital	IMPROVED EXPRESSION OF FACTOR IX IN GENTERAFFECTORS
US7998930B2 (en)	2004-11-04	2011-08-16	Hanall Biopharma Co., Ltd.	Modified growth hormones
CN101124328A (en)	2004-12-15	2008-02-13	北卡罗来纳查佩尔山大学	chimeric vector
ES2611608T3 (en)	2005-10-21	2017-05-09	Catalyst Biosciences, Inc.	Modified proteases that inhibit complement activation
US20070172846A1 (en)	2005-11-12	2007-07-26	Introgen Therapeutics, Inc.	Methods for the Production and Purification of Adenoviral Vectors
EP1791039A1 (en)	2005-11-25	2007-05-30	The Swatch Group Research and Development Ltd.	Hairspring made from athermic glass for a timepiece movement and its method of manufacture
DK1969127T4 (en)	2005-12-21	2017-10-16	Cnj Holdings Inc	Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
WO2007089632A2 (en)	2006-01-27	2007-08-09	The University Of North Carolina At Chapel Hill	Heparin and heparan sulfate binding chimeric vectors
WO2007101681A1 (en)	2006-03-07	2007-09-13	Baxter International Inc	Highly phosphorylated and sulfated recombinant factor ix
US20080003202A1 (en)	2006-03-28	2008-01-03	Thierry Guyon	Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en)	2006-03-30	2016-11-16	The Board Of Trustees Of The Leland Stanford Junior University	Aav capsid proteins
AU2007234698B2 (en)	2006-04-07	2013-08-01	The Board Of Regents Of The University Of Texas System	Methods and compositions related to adenoassociated virus-phage particles
RU2008145084A (en)	2006-05-24	2010-06-27	Ново Нордиск Хелс Кеа Аг (Ch)	ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
US20070280906A1 (en)	2006-06-03	2007-12-06	Ognjen Petras	Method to generate mirrored adenoassociated viral vectors
EP2037892B1 (en)	2006-06-19	2015-03-18	Asklepios Biopharmaceutical, Inc.	Modified factor viii and factor ix genes and vectors for gene therapy
US8383388B2 (en)	2006-06-19	2013-02-26	Catalyst Biosciences, Inc.	Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en)	2007-01-09	2010-04-20	Shu-Wha Lin	Recombinant human factor IX and use thereof
EP2108045B1 (en)	2007-02-01	2013-12-11	Baxter International Inc.	Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en)	2007-04-02	2008-10-09	Novo Nordisk A/S	Subcutaneous administration of coagulation factor ix
US20100137211A1 (en)	2007-04-11	2010-06-03	Monahan Paul E	Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (en)	2007-04-19	2008-12-09	Nautilus Biotech	oral dosage formulations of protease resistant polypeptides and their uses for treatment
US20080260820A1 (en)	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en)	2007-07-03	2009-01-29	Sucampo Ag	Pharmaceutical combination of opioid and prostaglandin compound
US20110154516A1 (en)	2007-10-15	2011-06-23	Stafford Darrel W	Human factor ix variants with an extended half life
CN102065887A (en)	2008-04-16	2011-05-18	拜耳医药保健有限公司	Site-directed modification of factor IX
KR20110005862A (en) *	2008-04-16	2011-01-19	바이엘 헬스케어 엘엘씨	Modified Factor I Polypeptides and Uses thereof
EP2268807A2 (en)	2008-04-21	2011-01-05	Novo Nordisk A/S	Hyperglycosylated human coagulation factor ix
EP2149603A1 (en)	2008-07-28	2010-02-03	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US9249405B2 (en)	2008-09-15	2016-02-02	Paolo Simioni	Factor IX polypeptide mutant, its uses and a method for its production
WO2010151736A1 (en)	2009-06-25	2010-12-29	The University Of North Carolina At Chapel Hill	Chimeric factor vii molecules
CA2769258A1 (en)	2009-07-31	2011-02-03	Bayer Healthcare Llc	Modified factor ix polypeptides and uses thereof
TWI595004B (en)	2010-11-03	2017-08-11	介控生化科技公司	Modified ninth factor multi-peptide and use thereof
EP3513802B1 (en)	2012-10-26	2023-11-29	Vrije Universiteit Brussel	Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en)	2013-12-09	2015-06-10	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2016004113A1 (en)	2014-06-30	2016-01-07	Biogen Ma Inc.	Optimized factor ix gene
ES2764453T3 (en)	2015-03-17	2020-06-03	Univ Brussel Vrije	Liver specific expression systems optimized for FVIII and FIX
CN115094062A (en)	2015-04-16	2022-09-23	埃默里大学	Recombinant promoter and vector for protein expression in liver and application thereof
CA2990193A1 (en)	2015-06-23	2016-12-29	The Children's Hospital Of Philadelphia	Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CA2994547A1 (en)	2015-08-03	2017-02-09	Bioverativ Therapeutics Inc.	Factor ix fusion proteins and methods of making and using same
WO2017180861A1 (en)	2016-04-15	2017-10-19	The Trustees Of The University Of Pennsulvania	Gene therapy for treating hemophilia b
KR102450833B1 (en)	2016-04-15	2022-10-05	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	Gene therapy for the treatment of hemophilia A
IL271957B2 (en)	2017-07-10	2024-02-01	Uniqure Ip Bv	Means and methods for aav gene therapy in humans
US20210228738A1 (en)	2017-07-17	2021-07-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

2009
- 2009-09-15 US US13/063,898 patent/US9249405B2/en not_active Ceased
- 2009-09-15 HR HRP20230259TT patent/HRP20230259T1/en unknown
- 2009-09-15 HR HRP20181442TT patent/HRP20181442T1/en unknown
- 2009-09-15 EP EP17175191.0A patent/EP3252157A1/en not_active Ceased
- 2009-09-15 US US18/153,894 patent/USRE50288E1/en active Active
- 2009-09-15 PL PL09748260T patent/PL2337849T3/en unknown
- 2009-09-15 LT LTEP19174517.3T patent/LT3581650T/en unknown
- 2009-09-15 EP EP19174517.3A patent/EP3581650B1/en active Active
- 2009-09-15 ES ES21200005T patent/ES2985035T3/en active Active
- 2009-09-15 ES ES19174517T patent/ES2940323T3/en active Active
- 2009-09-15 DK DK09748260.8T patent/DK2337849T3/en active
- 2009-09-15 HU HUE19174517A patent/HUE061345T2/en unknown
- 2009-09-15 EP EP09748260.8A patent/EP2337849B1/en not_active Revoked
- 2009-09-15 SI SI200932179T patent/SI3581650T1/en unknown
- 2009-09-15 TR TR2018/13067T patent/TR201813067T4/en unknown
- 2009-09-15 EP EP22214327.3A patent/EP4219547A3/en active Pending
- 2009-09-15 PL PL19174517.3T patent/PL3581650T3/en unknown
- 2009-09-15 PT PT191745173T patent/PT3581650T/en unknown
- 2009-09-15 SM SM20230084T patent/SMT202300084T1/en unknown
- 2009-09-15 SM SM20180468T patent/SMT201800468T1/en unknown
- 2009-09-15 PL PL21200005.3T patent/PL4032979T3/en unknown
- 2009-09-15 HU HUE21200005A patent/HUE067487T2/en unknown
- 2009-09-15 CA CA2737094A patent/CA2737094C/en active Active
- 2009-09-15 ES ES09748260.8T patent/ES2687038T3/en active Active
- 2009-09-15 EP EP21200005.3A patent/EP4032979B1/en active Active
- 2009-09-15 DK DK19174517.3T patent/DK3581650T3/en active
- 2009-09-15 FI FIEP19174517.3T patent/FI3581650T3/en active
- 2009-09-15 WO PCT/EP2009/061935 patent/WO2010029178A1/en not_active Ceased
2015
- 2015-12-29 US US14/981,981 patent/US20160122740A1/en not_active Abandoned
2017
- 2017-07-14 US US15/650,070 patent/US9982248B2/en active Active
2018
- 2018-03-21 HK HK18103924.5A patent/HK1244507A1/en unknown
- 2018-05-25 US US15/989,665 patent/US10465180B2/en active Active
2019
- 2019-10-01 US US16/589,851 patent/US20200231958A1/en not_active Abandoned
- 2019-12-09 US US16/707,414 patent/US20200190498A1/en not_active Abandoned
2020
- 2020-02-11 US US16/787,456 patent/US20200199564A1/en not_active Abandoned
2021
- 2021-03-26 US US17/213,897 patent/US20210214704A1/en active Pending
- 2021-03-26 US US17/213,848 patent/US20210238573A1/en not_active Abandoned
- 2021-09-10 US US17/447,372 patent/US20220002702A1/en not_active Abandoned
- 2021-12-08 US US17/643,326 patent/US20220090042A1/en not_active Abandoned
2023
- 2023-03-14 CY CY20231100138T patent/CY1125885T1/en unknown
- 2023-07-25 FI FIC20230026C patent/FIC20230026I1/en unknown
- 2023-07-25 HU HUS2300024C patent/HUS2300024I1/en unknown
- 2023-07-26 FR FR23C1028C patent/FR23C1028I1/en active Active
- 2023-07-27 LT LTPA2023521C patent/LTPA2023521I1/lt unknown
- 2023-07-27 CY CY2023016C patent/CY2023016I1/en unknown
- 2023-07-31 NO NO2023029C patent/NO2023029I1/en unknown
2024
- 2024-10-29 LT LTPA2024530C patent/LTPA2024530I1/lt unknown
- 2024-10-29 LT LTPA2024529C patent/LTPA2024529I1/lt unknown
- 2024-10-29 FI FIC20240037C patent/FIC20240037I1/en unknown
- 2024-10-29 FI FIC20240036C patent/FIC20240036I1/en unknown
- 2024-10-30 FR FR24C1041C patent/FR24C1041I1/en active Active
- 2024-10-30 HU HUS2400037C patent/HUS2400037I1/en unknown
- 2024-10-30 FR FR24C1040C patent/FR24C1040I1/en active Active
- 2024-10-30 HU HUS2400036C patent/HUS2400036I1/en unknown
2025
- 2025-01-16 US US19/024,178 patent/US20250179462A1/en not_active Abandoned
- 2025-01-21 FR FR25C1004C patent/FR25C1004I1/en active Active
- 2025-01-21 NO NO2025007C patent/NO2025007I1/en unknown
- 2025-01-22 FI FIC20250007C patent/FIC20250007I1/en unknown
- 2025-01-23 HU HUS2500006C patent/HUS2500006I1/en unknown
- 2025-01-23 LT LTPA2025503C patent/LTPA2025503I1/lt unknown

Also Published As

Publication number	Publication date
EP3581650B1 (en)	2022-12-28
PL3581650T3 (en)	2023-05-22
LTPA2024529I1 (en)	2024-12-10
HRP20181442T1 (en)	2018-12-14
EP4032979A1 (en)	2022-07-27
HUS2400036I1 (en)	2024-11-28
LTPA2025503I1 (en)	2025-02-10
HUE061345T2 (en)	2023-06-28
US20220002702A1 (en)	2022-01-06
WO2010029178A1 (en)	2010-03-18
ES2985035T3 (en)	2024-11-04
SMT201800468T1 (en)	2018-11-09
US20200190498A1 (en)	2020-06-18
EP4032979C0 (en)	2024-05-01
US9982248B2 (en)	2018-05-29
EP4219547A3 (en)	2023-10-18
CA2737094A1 (en)	2010-03-18
CY1125885T1 (en)	2024-02-16
LTPA2023521I1 (en)	2023-08-25
ES2940323T3 (en)	2023-05-05
SI3581650T1 (en)	2023-06-30
LT3581650T (en)	2023-05-10
EP2337849A1 (en)	2011-06-29
US20200231958A1 (en)	2020-07-23
HK1244507A1 (en)	2018-08-10
US20220090042A1 (en)	2022-03-24
US20250179462A1 (en)	2025-06-05
US9249405B2 (en)	2016-02-02
DK2337849T3 (en)	2018-10-01
USRE50288E1 (en)	2025-02-04
CA2737094F (en)	2010-03-18
FIC20250007I1 (en)	2025-01-22
HUE067487T2 (en)	2024-10-28
DK3581650T3 (en)	2023-03-13
PL2337849T3 (en)	2018-11-30
EP4219547A2 (en)	2023-08-02
TR201813067T4 (en)	2018-09-21
PL4032979T3 (en)	2024-09-30
EP4032979B1 (en)	2024-05-01
US20160122740A1 (en)	2016-05-05
NO2023029I1 (en)	2023-07-31
US20210238573A1 (en)	2021-08-05
CY2023016I2 (en)	2024-02-16
US20110244550A1 (en)	2011-10-06
FR23C1028I1 (en)	2023-10-06
CY2023016I1 (en)	2024-02-16
US10465180B2 (en)	2019-11-05
CA2737094C (en)	2018-02-20
FIC20230026I1 (en)	2023-07-25
HUS2300024I1 (en)	2023-08-28
HRP20230259T1 (en)	2023-04-28
HUS2500006I1 (en)	2025-02-28
FR24C1040I1 (en)	2024-12-06
EP3581650A3 (en)	2020-03-25
US20200199564A1 (en)	2020-06-25
FIC20240037I1 (en)	2024-10-30
US20170355973A1 (en)	2017-12-14
LTPA2024530I1 (en)	2024-11-25
EP3252157A1 (en)	2017-12-06
NO2025007I1 (en)	2025-01-21
FI3581650T3 (en)	2023-03-23
FR25C1004I1 (en)	2025-02-28
US20210214704A1 (en)	2021-07-15
EP2337849B1 (en)	2018-06-13
FIC20240036I1 (en)	2024-10-29
ES2687038T3 (en)	2018-10-23
SMT202300084T1 (en)	2023-05-12
PT3581650T (en)	2023-03-08
US20180258413A1 (en)	2018-09-13
EP3581650A2 (en)	2019-12-18
HUS2400037I1 (en)	2024-11-28

Publication	Publication Date	Title
FR25C1004I1 (en)	2025-02-28	FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND PRODUCTION METHOD
EP2540385A4 (en)	2015-05-27	COMPOSITE SEMIPERMABLE MEMBRANE AND METHOD FOR PRODUCING THE SAME
EP2437332A4 (en)	2014-01-22	POSITIVE ELECTRODE AND METHOD FOR PRODUCING THE SAME
EP2695907A4 (en)	2014-09-10	POROUS MEMBRANE AND METHOD FOR PRODUCING THE SAME
EP2264079A4 (en)	2011-03-16	COPOLYMER AND METHOD FOR PRODUCING THE SAME
EP2669315A4 (en)	2014-10-29	POLYANILINE COMPOSITE, METHOD FOR PRODUCING THE SAME, AND COMPOSITION
EP2354180A4 (en)	2013-02-20	POROUS POLYIMIDE MEMBRANE AND METHOD FOR PRODUCING THE SAME
EP2540796A4 (en)	2014-07-23	Β-SIALON LUMINOPHORE, ITS USES, METHOD FOR PRODUCING LUMINOPHORE β-SIALON
EP2475226A4 (en)	2013-03-27	LUMINESCENT ELEMENT AND METHOD FOR PRODUCING THE SAME, AND LUMINESCENT DEVICE
EP2650127A4 (en)	2015-11-18	ANTICONDENSATION ARTICLE AND METHOD FOR PRODUCING THE SAME
EP2618139A4 (en)	2016-12-28	BIOSENSOR AND METHOD FOR PRODUCING THE SAME
EP2337679A4 (en)	2012-04-25	DECORATIVE CLOTHING AND METHOD FOR MANUFACTURING THE SAME
EP2095286A4 (en)	2011-05-11	INTELLIGENT PRODUCTION STATION AND METHOD FOR PRODUCING THE SAME
EP2607307A4 (en)	2014-06-18	POLYCRYSTALLINE DIAMOND AND PROCESS FOR PRODUCING THE SAME
EP2613378A4 (en)	2014-01-15	POROUS COMPOSITE FILM AND METHOD FOR PRODUCING THE SAME
EP2799095A4 (en)	2015-08-19	DENTAL IMPLANT HAVING ENHANCED EARLY STABILITY AND METHOD FOR PRODUCING THE SAME
EP2284204A4 (en)	2011-08-10	COPOLYMER, METHOD FOR PRODUCING THE SAME, AND WATER-REPELLENT AND OIL-REPELLENT COMPOSITION
EP2599800A4 (en)	2014-06-11	COPOLYMER AND METHOD FOR PRODUCING THE SAME
EP2269818A4 (en)	2015-01-07	POLYMERIZED FILM AND METHOD FOR PRODUCING THE SAME
EP2781577A4 (en)	2015-03-25	NITRIDE PHOSPHOR AND METHOD FOR PRODUCING THE SAME
EP2261275A4 (en)	2012-01-25	MICROPOROUS FILM AND METHOD FOR PRODUCING THE SAME
EP2725042A4 (en)	2014-11-05	POLYMER AND METHOD FOR PRODUCING THE SAME
EP2276691A4 (en)	2013-08-28	METAL NANOPEPONENT WITHOUT TEMPLES AND WITHOUT POLYMER, AND METHOD FOR PRODUCING THE SAME
EP2647661A4 (en)	2013-10-09	MICROPOROUS MEMBRANE AND METHOD FOR PRODUCING THE SAME
EP2242976A4 (en)	2012-08-01	ELECTRODE AND METHOD FOR PRODUCING THE SAME